Your heart and your brain may be more deeply connected than most people realize—and the damage can start long before obvious symptoms appear. And this is the part most people miss: changes in the brain can be quietly progressing even when memory tests still look “normal.”
Researchers have been looking at people with coronary artery disease (CAD), a condition where the blood vessels that nourish the heart become narrowed or blocked. In addition to raising the risk of heart attacks and strokes, CAD has also been linked to a higher likelihood of cognitive problems and dementia, but the biological bridge between heart disease and brain decline has not been completely clear.
A recent study led by a team at Concordia University set out to explore that bridge by focusing on white matter in the brain—the network of long nerve fibers that act like high-speed communication cables connecting different brain regions. Healthy white matter helps information move quickly and efficiently, supporting everything from attention and thinking speed to movement and coordination. When white matter is damaged, those processes can slow down, sometimes in ways that are too subtle to notice at first but that can build up over time.
The study, published in the Journal of Neuroscience, used an advanced statistical method called a multivariate approach and drew on 12 different white matter measurements to capture a detailed picture of brain structure. Researchers compared MRI scans and cognitive test results from 43 adults over age 50 with CAD to those from 36 similarly aged people without the disease. By analyzing many white matter metrics together rather than one at a time, they aimed to detect small but meaningful patterns that older methods might have missed.
The findings were striking: people with CAD showed widespread structural alterations in their white matter compared with healthy participants. These differences were especially pronounced in brain areas supplied by the middle cerebral artery (MCA) and anterior cerebral artery—regions that play key roles in thinking, decision-making, and movement. The MCA territory, in particular, is known to be highly vulnerable to strokes, which makes these changes especially concerning. But here’s where it gets controversial: none of the CAD participants had a history of stroke, yet their brains still showed significant structural changes.
The research team deliberately selected individuals with CAD who had no previous strokes because they wanted to understand what happens early in the course of heart disease, before obvious brain injuries or clinical events appear. Their goal was to capture the “silent phase,” when damage may already be starting but symptoms are too subtle for standard neurological exams to pick up. This early window is crucial, because it may offer a chance to intervene before memory loss or other cognitive issues become apparent in everyday life.
One of the innovative aspects of this work was how the researchers combined multiple white matter measurements into a single overall metric. Rather than looking at each measure separately (a univariate approach), they bundled them together into a summary score that reflects many different aspects of white matter health at once. Even if each individual metric only showed a tiny difference between CAD patients and healthy controls, the combined metric could reveal a clearer, stronger signal of early brain changes. It is a bit like noticing that each warning light on a dashboard is only dimly lit, but together they clearly indicate that something is wrong with the engine.
The team noted that many of these white matter measurements overlap, meaning they capture related features of brain tissue structure. Using a single multivariate metric helped them detect complex patterns of alteration and then “unpack” that signal to see which specific properties contributed the most. This way, they could identify which aspects of white matter health—such as how well fibers are insulated or how densely they are packed—were most affected in people with CAD. This approach offers a more holistic look at brain integrity compared with simpler one-metric-at-a-time analyses.
A key result pointed toward myelin, the fatty, protective coating that wraps around nerve fibers and enables electrical signals to travel rapidly along them. The researchers found that the structural changes in CAD patients were largely associated with reduced myelin content in white matter. When myelin breaks down or thins, communication between brain cells slows, which can contribute to cognitive aging and may set the stage for later problems with thinking, attention, or coordination. But here’s where it gets controversial: these microstructural changes could be happening years before standard clinical tests call anything “abnormal.”
The study also showed that participants who had higher measures of myelin integrity—especially in a marker known as R1—tended to perform better on tasks that measured processing speed. Processing speed is a core component of cognition that reflects how quickly a person can take in, understand, and respond to information, and it underpins many everyday activities like driving, problem-solving, or following conversations. This suggests that preserving myelin health may be directly linked to keeping the brain fast and efficient.
Interestingly, when the researchers compared overall cognitive scores between the CAD group and the healthy control group, they did not find significant differences. On the surface, this could make it seem as if CAD is not yet affecting thinking ability, but the imaging results tell a different story. The mismatch between “normal” cognitive scores and altered white matter structure suggests that the brain may be compensating, at least for now, and that structural damage may precede noticeable symptoms by years. And this is the part most people miss: by the time everyday memory or attention problems become obvious, underlying brain changes may already be well established.
According to the authors, the study adds important mechanistic insight into how coronary artery disease might gradually influence brain health through its impact on white matter. Identifying myelin content as a promising biomarker for coronary heart disease opens the door to monitoring brain changes more precisely and potentially catching risk earlier. If clinicians can reliably track how myelin is doing in vulnerable regions of the brain, they may be able to flag individuals who look cognitively “fine” today but are at higher risk of future decline.
Looking ahead, the researchers emphasize the importance of focusing on interventions that can protect or improve myelin health in people with CAD. Lifestyle changes such as regular physical activity, a heart-healthy diet, good sleep, stress management, and controlling blood pressure and cholesterol are already known to support both cardiovascular and brain health. This study suggests that these strategies might be especially relevant for preserving myelin and maintaining processing speed over time, though more targeted trials are needed to determine exactly which interventions make the biggest difference.
The work received support from major Canadian funding organizations, including the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, and Brain Canada. Their backing reflects a growing recognition that heart and brain health are deeply intertwined rather than separate topics. As research continues, combining advanced brain imaging with careful cognitive testing and lifestyle data may help build a more complete map of how cardiovascular disease shapes brain aging across decades.
Here’s a thought-provoking angle that could spark debate: if structural brain changes can be detected in CAD patients before any clear cognitive impairment, should brain imaging become a routine part of heart disease evaluation, or would that be too costly, anxiety-provoking, or premature? And if early white matter changes become widely accepted as warning signs, could people be labeled “at risk” long before they experience any symptoms, for better or for worse?
What do you think: should cardiology and neurology be working far more closely together to screen for and protect brain health in people with coronary artery disease, or is this level of testing and prediction a step too far? Do you agree that subtle brain changes should be treated as early red flags, or do you worry about overdiagnosis and unnecessary interventions? Share where you stand—does this research reassure you, concern you, or change how you think about the connection between heart health and cognitive aging?
